Literature DB >> 14656475

Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells.

Yasunori Hoshiya1, Vandana Gupta, Dorry L Segev, Makiko Hoshiya, Jennifer L Carey, Laura M Sasur, Trinh T Tran, Thanh U Ha, Shyamala Maheswaran.   

Abstract

The MIS type II receptor is expressed at high levels in the Mullerian duct and in Sertoli cells and granulosa cells of the embryonic and adult gonads. The presence of MIS type II and type I receptors in tissues and cell lines derived from breast and prostate suggests that the prostate and mammary glands may be additional targets for MIS action. In both breast and prostate cancer cells, MIS activated NFkB DNA binding activity and induced IEX-1, an immediate early gene which regulates cell growth and apoptosis. Exposure of cells to MIS inhibited growth by increasing the fraction of cells in the G1 phase of the cell cycle and by inducing apoptosis. These results suggest that MIS may be a putative mediator of growth regulatory signals in the breast and prostate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656475     DOI: 10.1016/j.mce.2003.09.010

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  26 in total

1.  Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk.

Authors:  Hazel B Nichols; Donna D Baird; Frank Z Stanczyk; Anne Z Steiner; Melissa A Troester; Kristina W Whitworth; Dale P Sandler
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

2.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

3.  CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.

Authors:  Alba Rodriguez-Garcia; Prannda Sharma; Mathilde Poussin; Alina C Boesteanu; Nicholas G Minutolo; Sarah B Gitto; Dalia K Omran; Matthew K Robinson; Gregory P Adams; Fiona Simpkins; Daniel J Powell
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

4.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

5.  Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

Authors:  V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

6.  Prediagnostic circulating anti-Müllerian hormone concentrations are not associated with prostate cancer risk.

Authors:  Martha M Sklavos; Cindy Ke Zhou; Ligia A Pinto; Michael B Cook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-26       Impact factor: 4.254

7.  Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Authors:  Henry L Chang; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Xianlin Li; Xiaolong Wei; David T MacLaughlin; Patricia K Donahoe
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

Review 8.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

9.  Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells.

Authors:  Peter J Malloy; Lihong Peng; Jining Wang; David Feldman
Journal:  Endocrinology       Date:  2008-12-04       Impact factor: 4.736

10.  Serum anti-mullerian hormone and all-cause mortality in men.

Authors:  Rehan Qayyum; Sana Akbar
Journal:  Endocrine       Date:  2016-08-08       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.